- Home
- CLNN vs PLRX Comparison
CLNN vs PLRX Comparison
Compare CLNN & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLNN | PLRX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | 49 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4M | 63.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CLNN | PLRX |
|---|---|---|
| Price | $3.86 | $1.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $32.20 | $2.67 |
| AVG Volume (30 Days) | 121.9K | ★ 353.8K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $200,000.00 | N/A |
| Revenue This Year | $24.70 | N/A |
| Revenue Next Year | $9,228.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.25 | $0.97 |
| 52 Week High | $13.50 | $1.95 |
Technical Indicators
Market Signals| Indicator | CLNN | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.32 | 37.32 |
| Support Level | $3.25 | N/A |
| Resistance Level | $4.70 | $1.37 |
| Average True Range (ATR) | 0.27 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 15.16 | 25.00 |
Price Performance
Historical ComparisonAbout CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.